celecoxib and Cancer of Colon studies

Research Excerpts

Excerpt	Relevance	Reference
"Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP)."	9.14	The safety and efficacy of celecoxib in children with familial adenomatous polyposis. ( Ayers, GD; Burke, CA; Church, J; Eagle, C; Half, E; Hasson, H; Hawk, E; Lynch, PM; Patterson, S; Richmond, E; Woloj, M, 2010)
"This study was designated to explore the role of cancer stem cells (CSCs) during chemically induced mouse colon carcinogenesis (by 1,2- dimethylhydrazine dihydrochloride, DMH) with/or without the treatment with a targeted (anti-COX-2) therapeutic drug, celecoxib."	7.91	Celecoxib Targeted Therapy Attenuates Mouse Colon Carcinogenesis through Modulation of Expression Patterns of Cancer Stem Cells. ( Eltonouby, EA; Hegazi, MM; Helmy, HM; Kang, JS; Mahfouz, ME; Salim, EI, 2019)
"The purpose of this study was to investigate the role of colon cancer stem cells (CSCs) during chemicallyinduced rat multi-step colon carcinogenesis with or without the treatment with a specific cyclooxygenase-2 inhibitor drug (celecoxib)."	7.83	Expression Patterns of Cancer Stem Cell Markers During Specific Celecoxib Therapy in Multistep Rat Colon Carcinogenesis Bioassays. ( Hegazi, MM; Helmy, HM; Kang, JS; Salim, EI, 2016)
"This study was performed to evaluate whether down-regulation of prostaglandin E(2) (PGE(2)) synthesis by celecoxib treatment is associated with inhibition of cell growth in human colon carcinoma cell lines."	7.74	Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines. ( Arber, N; Ben-Yosef, R; Kazanov, D; Lev-Ari, S; Liberman, E, 2007)
"Celecoxib has proven to be a very prominent member of this group with cytostatic activities."	5.51	Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. ( Buzharevski, A; Hey-Hawkins, E; Laube, M; Lönnecke, P; Maksimovic-Ivanic, D; Mijatovic, S; Neumann, W; Paskas, S; Pietzsch, J; Sárosi, MB, 2019)
"Local recurrence in colon cancer causes poor prognosis affecting overall survival of cancer-affected patient population."	5.43	Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. ( Chaurasia, M; Chowdhury, T; Das, S; Dey, KK; Mandal, M; Pal, I; Parida, S; Rajesh, Y; Sharma, K, 2016)
"HT-29 colon cancer cells and LT97 colorectal micro-adenoma cells derived from a patient with FAP, were exposed to low dose celecoxib and UDCA alone or in combination with tauro-cholic acid (CA) and tauro-chenodeoxycholic acid (CDCA), mimicking bile of FAP patients treated with UDCA."	5.38	Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. ( Marian, B; Nagengast, FM; Peters, WH; Roelofs, HM; Te Morsche, RH; van Heumen, BW, 2012)
"Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP)."	5.14	The safety and efficacy of celecoxib in children with familial adenomatous polyposis. ( Ayers, GD; Burke, CA; Church, J; Eagle, C; Half, E; Hasson, H; Hawk, E; Lynch, PM; Patterson, S; Richmond, E; Woloj, M, 2010)
"NSAIDs such as celecoxib and sulindac play a critical role in the treatment of colorectal cancer, yet it is not understood how sufficiently high concentrations are reached in colonic tissue."	4.02	Insight into the Colonic Disposition of Sulindac in Humans. ( Augustijns, P; Brouwers, J; Lemmens, G; Snoeys, J; Vanuytsel, T, 2021)
"This study was designated to explore the role of cancer stem cells (CSCs) during chemically induced mouse colon carcinogenesis (by 1,2- dimethylhydrazine dihydrochloride, DMH) with/or without the treatment with a targeted (anti-COX-2) therapeutic drug, celecoxib."	3.91	Celecoxib Targeted Therapy Attenuates Mouse Colon Carcinogenesis through Modulation of Expression Patterns of Cancer Stem Cells. ( Eltonouby, EA; Hegazi, MM; Helmy, HM; Kang, JS; Mahfouz, ME; Salim, EI, 2019)
"The purpose of this study was to investigate the role of colon cancer stem cells (CSCs) during chemicallyinduced rat multi-step colon carcinogenesis with or without the treatment with a specific cyclooxygenase-2 inhibitor drug (celecoxib)."	3.83	Expression Patterns of Cancer Stem Cell Markers During Specific Celecoxib Therapy in Multistep Rat Colon Carcinogenesis Bioassays. ( Hegazi, MM; Helmy, HM; Kang, JS; Salim, EI, 2016)
"Several studies have shown the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) on 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis, but how these drugs act in case of inflammation-augmented tumorigenesis is still not clear."	3.80	Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis. ( Nehru, B; Sanyal, SN; Setia, S, 2014)
"The expression of the putative markers LGR-5 (leucine-rich-repeat-containing G-protein-coupled receptor 5), MSI-1 (Musashi-1) and DCAMKL-1 (doublecortin and calcium/calmodulin-dependent protein kinase-like-1) was studied in normal colon mucosa (NM), in the precancerous lesions Mucin Depleted Foci (MDF) and in macroscopic tumours (adenomas) of 1,2-dimethylhydrazine-treated rats."	3.79	Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin. ( Caderni, G; Dolara, P; Femia, AP; Salvadori, M, 2013)
"This study was performed to evaluate whether down-regulation of prostaglandin E(2) (PGE(2)) synthesis by celecoxib treatment is associated with inhibition of cell growth in human colon carcinoma cell lines."	3.74	Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines. ( Arber, N; Ben-Yosef, R; Kazanov, D; Lev-Ari, S; Liberman, E, 2007)
"Elevated polyamine and nitric oxide levels (both derived from arginine) promote tumorigenesis, whereas non-steroidal anti-inflammatory drugs (NSAIDs) inhibit colorectal cancer (CRC) incidence in experimental and epidemiologic studies."	3.74	Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. ( Anton-Culver, H; Besselsen, DG; Gerner, EW; Ignatenko, NA; Yerushalmi, HF; Zell, JA; Ziogas, A, 2007)
"A total of 2526 patients with stage III colon cancer were enrolled between June 2010 and November 2015 and were followed up through August 10, 2020."	3.01	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. ( Bendell, JC; Bertagnolli, M; Blanke, C; Couture, F; Fuchs, CS; Goldberg, RM; Grothey, A; Guthrie, KA; Hochster, HS; Kuebler, P; Kumar, P; Kumthekar, P; Lewis, D; Meyer, J; Meyerhardt, JA; Niedzwiecki, D; O'Reilly, EM; Shi, Q; Shields, AF; Tan, B; Venook, A; Zemla, T, 2021)
"Celecoxib has been accounted to be an effective antitumor drug, but may exhibit significant side effects."	1.91	ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells. ( Cai, F; Hua, ZC; Li, P; Ma, H; Sun, H; Tan, Y; Wang, X; Xu, H; Xu, J; Zhuang, H, 2023)
"PIP as a bioenhancer increased the oral bioavailability of CXB (129%)."	1.62	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/β-catenin signaling pathway. ( Chaturvedi, S; Dewangan, J; Divakar, A; Kumar, S; Mishra, S; Rath, SK; Srivastava, S; Wahajuddin, M, 2021)
"The fifth case was a breast cancer patient with distant metastases in CR, while receiving beta-interferon and interleukin-2 in addition to conventional hormone therapy."	1.51	Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. ( Carpi, A; Ferrari, P; Morganti, R; Nicolini, A, 2019)
"Celecoxib has proven to be a very prominent member of this group with cytostatic activities."	1.51	Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. ( Buzharevski, A; Hey-Hawkins, E; Laube, M; Lönnecke, P; Maksimovic-Ivanic, D; Mijatovic, S; Neumann, W; Paskas, S; Pietzsch, J; Sárosi, MB, 2019)
"Local recurrence in colon cancer causes poor prognosis affecting overall survival of cancer-affected patient population."	1.43	Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. ( Chaurasia, M; Chowdhury, T; Das, S; Dey, KK; Mandal, M; Pal, I; Parida, S; Rajesh, Y; Sharma, K, 2016)
"We used gastric and colon cancer cell lines to study the synergistic effect of As4S4 in combination with BRD4 inhibitor JQ1, or with chemotherapy drug cisplatin and irinotecan or with COX2 inhibitor celecoxib."	1.42	Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. ( Chen, S; Pan, M; Tong, Y; Zhang, L; Zhang, X, 2015)
"CD133-positive cancer stem cells in colon cancer are resistant to conventional chemotherapy."	1.39	Celecoxib downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells. ( Deng, Y; Fu, X; Lin, EH; Mo, J; Su, Q; Zhang, Y, 2013)
"Celecoxib treatment activated Cdc25C and inhibited p21 expression in both unirradiated and irradiated cells, regardless of COX-2 expression."	1.39	Different cell cycle modulation by celecoxib at different concentrations. ( Kim, YM; Pyo, H, 2013)
"Celecoxib combined with 5-FU could inhibit the growth of tumors in vivo by inducing apoptosis and activation of the cytochrome C dependency apoptosis signal pathway."	1.39	Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. ( Chen, WC; Guo, Q; Zhang, DQ; Zhu, JH, 2013)
"Human HT-29 colon cancer cells were exposed to carefully controlled hypoxic conditions and/or epidermal growth factor (EGF) and then investigated for EMT changes and signal transduction pathways involved by using morphological, molecular, and cell biology techniques."	1.38	Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. ( Bocca, C; Bozzo, F; Cannito, S; Miglietta, A; Parola, M, 2012)
"HT-29 colon cancer cells and LT97 colorectal micro-adenoma cells derived from a patient with FAP, were exposed to low dose celecoxib and UDCA alone or in combination with tauro-cholic acid (CA) and tauro-chenodeoxycholic acid (CDCA), mimicking bile of FAP patients treated with UDCA."	1.38	Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. ( Marian, B; Nagengast, FM; Peters, WH; Roelofs, HM; Te Morsche, RH; van Heumen, BW, 2012)
"Combined treatment of human HCT116 colon cancer cells with free celecoxib plus tributyrin emulsion inhibited the cellular proliferation more effectively than that of each drug alone, suggesting the possibility of tributyrin emulsion as a potential celecoxib carrier."	1.38	Dual function of tributyrin emulsion: solubilization and enhancement of anticancer effect of celecoxib. ( Hong, SS; Kang, SN; Lee, MK; Lim, SJ, 2012)
"Celecoxib has shown potential anticancer activity against most carcinomas, especially in patients with familial adenomatous polyposis and precancerous disease of the colon."	1.37	The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. ( Azab, B; Dash, R; Fisher, PB; Kundu, SC; Mandal, M; Pathak, A; Prashanth Kumar, BN; Puvvada, N; Sarkar, D; Venkatesan, P, 2011)
"Leukotriene B4 (LTB4) has been implicated in prostate and colon carcinogenesis, but little is known about the potential role of LTB4 in celecoxib-mediated anticancer effect."	1.36	Role of leukotriene B4 in celecoxib-mediated anticancer effect. ( Gao, P; Guan, L; Zheng, J, 2010)
"Therefore, two clones of a human colon cancer cell line (HT-29) in which GPx2 was stably knocked down by small interfering RNA (siRNA; siGPx2) were used to test whether cancer-relevant processes are affected by GPx2."	1.35	Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice. ( Banning, A; Brigelius-Flohé, R; Florian, S; Kipp, A; Krehl, S; Löwinger, M; Schmitmeier, S; Steinberg, P; Thalmann, S; Thierbach, R, 2008)
"Progression of colon cancer is associated with the up-regulation of cyclooxygenase-2 (COX-2) and hydroxymethyl glutaryl CoA reductase (HMG-R)."	1.35	Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. ( Guruswamy, S; Rao, CV, 2009)
"Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) developed as a selective inhibitor of cyclooxygenase-2 (COX-2)."	1.35	Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth. ( Bassignana, A; Bocca, C; Boschi, D; Bozzo, F; Gasco, A; Lazzarato, L; Miglietta, A, 2009)
"To evaluate the effects of celecoxib, in combination with oxaliplatin, on tumour growth, cell apoptosis and angiogenesis in nude mice models."	1.35	Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. ( Bian, H; Cai, J; Gui, L; Zhao, F; Zhao, S, 2009)
"Celecoxib treatment resulted in significantly altered expression levels of over 1,000 to 3,000 transcripts in these cell lines, respectively."	1.35	Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib. ( Ajaz, S; Ali, IU; Fatima, N; Greenwald, P; Munroe, DJ; Stauffer, S; Stephens, RM; Yi, M, 2008)
"Celecoxib was incubated for 4 h with HT29 cells and HUVEC and adhesion was quantified by a computerized micro-imaging system."	1.35	Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression. ( Brucato, L; Collino, M; Dianzani, C; Fantozzi, R; Gallicchio, M; Rosa, AC, 2008)
"Two human colon cancer cell lines (HCT-15 and HT-29) were treated with 5-FU and celecoxib, alone and in combination."	1.34	Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. ( Bae, YM; Chun, WJ; Lim, YJ; Rhee, JC, 2007)
"The proliferation of colon cancer cells was determined by MTT assay, and the cell cycle progression was analyzed by flow cytometric assay."	1.33	[Effects of selective and non-selective cyclooxygenase-2 inhibitor on the growth of colon cancer cells]. ( Huang, MH; Li, X; Ouyang, Q; Tang, CW; Wang, CH, 2006)
" Chronic use of high doses of these agents may induce side effects in ostensibly normal individuals."	1.33	Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. ( Khor, TO; Kong, AN; Kopelovich, L; Rao, CV; Reddy, BS; Steele, VE; Wang, CX; Zheng, X, 2006)
" This study examined the dose-response effect of celecoxib when administered during the initiation and postinitiation stages."	1.31	Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. ( Hirose, Y; Kelloff, G; Lubet, R; Paulson, S; Rao, CV; Reddy, BS; Seibert, K; Steele, V, 2000)
" Groups 2 and 3 also received experimental diet containing celecoxib (500 and 1500 ppm, respectively) for 8 weeks, starting a week before the first dosing of AOM."	1.31	Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. ( Hara, A; Hirose, Y; Katayama, M; Kuno, T; Mori, H; Qiao, Z; Shimizu, M; Yamada, Y; Yoshimi, N, 2001)
"Celecoxib was more potent than SC560."	1.31	COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. ( Bräutigam, L; Geisslinger, G; Grösch, S; Niederberger, E; Tegeder, I, 2001)
" Experiments were designed to assess the potential chemopreventive properties of highly selective iNOS inhibitors, administered individually and in combination with a selective COX-2 inhibitor, on the development of AOM-induced colonic aberrant crypt foci (ACF)."	1.31	Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. ( Connor, JR; Indranie, C; Manning, PT; Rao, CV; Reddy, BS; Simi, B, 2002)

Research

Studies (119)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Disease-free Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (3.36)	18.2507
2000's	58 (48.74)	29.6817
2010's	49 (41.18)	24.3611
2020's	8 (6.72)	2.80

Authors	Studies
Ottanà, R	1
Carotti, S	1
Maccari, R	1
Landini, I	1
Chiricosta, G	1
Caciagli, B	1
Vigorita, MG	1
Mini, E	1
Ruiz, JF	1
Kedziora, K	1
Keogh, B	1
Maguire, J	1
Reilly, M	1
Windle, H	1
Kelleher, DP	1
Gilmer, JF	1
Bhardwaj, A	2
Kaur, J	2
Sharma, SK	1
Huang, Z	1
Wuest, F	2
Knaus, EE	2
Misra, S	1
Ghatak, S	1
Patil, N	1
Dandawate, P	1
Ambike, V	1
Adsule, S	1
Unni, D	1
Venkateswara Swamy, K	1
Padhye, S	1
Maruyama, R	1
Kiyohara, Y	1
Kudo, Y	1
Sugiyama, T	1
Xu, H	1
Li, P	1
Ma, H	1
Tan, Y	1
Wang, X	1
Cai, F	1
Xu, J	1
Sun, H	1
Zhuang, H	1
Hua, ZC	1
Nicolini, A	1
Ferrari, P	1
Morganti, R	1
Carpi, A	1
Salim, EI	2
Mahfouz, ME	1
Kang, JS	2
Hegazi, MM	2
Helmy, HM	2
Eltonouby, EA	1
Lemmens, G	1
Brouwers, J	1
Snoeys, J	1
Augustijns, P	1
Vanuytsel, T	1
Mao, L	1
Yang, J	1
Yue, J	1
Chen, Y	2
Zhou, H	1
Fan, D	1
Zhang, Q	3
Buraschi, S	1
Iozzo, RV	1
Bi, X	1
Srivastava, S	1
Dewangan, J	1
Mishra, S	1
Divakar, A	1
Chaturvedi, S	1
Wahajuddin, M	1
Kumar, S	1
Rath, SK	1
Yin, X	1
Zhang, Y	3
Wen, Y	1
Yang, Y	1
Chen, H	1
Kerr, DJ	1
Chamberlain, S	1
Kerr, RS	1
Meyerhardt, JA	1
Shi, Q	1
Fuchs, CS	1
Meyer, J	1
Niedzwiecki, D	1
Zemla, T	1
Kumthekar, P	1
Guthrie, KA	1
Couture, F	1
Kuebler, P	1
Bendell, JC	1
Kumar, P	1
Lewis, D	1
Tan, B	1
Bertagnolli, M	1
Grothey, A	1
Hochster, HS	1
Goldberg, RM	1
Venook, A	1
Blanke, C	1
O'Reilly, EM	1
Shields, AF	1
Jain, S	2
Ghanghas, P	2
Rana, C	4
Sanyal, SN	10
Buzharevski, A	1
Paskas, S	1
Sárosi, MB	1
Laube, M	1
Lönnecke, P	1
Neumann, W	1
Mijatovic, S	1
Maksimovic-Ivanic, D	1
Pietzsch, J	1
Hey-Hawkins, E	1
Piplani, H	3
Vaish, V	4
Vaiphei, K	1
Setia, S	3
Nehru, B	4
Liu, Z	1
Duan, ZJ	1
Chang, JY	1
Zhang, ZF	1
Chu, R	1
Li, YL	1
Dai, KH	1
Mo, GQ	1
Chang, QY	1
Edagawa, M	1
Kawauchi, J	1
Hirata, M	2
Goshima, H	1
Inoue, M	1
Okamoto, T	1
Murakami, A	1
Maehara, Y	1
Kitajima, S	1
Kim, SJ	1
Ha, GH	1
Bae, JH	1
Kim, GR	1
Son, CH	1
Park, YS	1
Yang, K	1
Oh, SO	1
Kim, SH	1
Kang, CD	1
Fink, SP	2
Dawson, DM	1
Kresak, A	1
Lawrence, EG	1
Yang, P	2
Barnholtz-Sloan, JS	2
Willis, JE	1
Kopelovich, L	2
Markowitz, SD	2
Venè, R	1
Tosetti, F	1
Minghelli, S	1
Poggi, A	1
Ferrari, N	1
Benelli, R	1
Tian, S	1
Chang, W	1
Du, H	1
Bai, J	1
Sun, Z	1
Wang, H	1
Zhu, G	1
Tao, K	1
Long, Y	1
Zhang, L	1
Tong, Y	1
Zhang, X	1
Pan, M	1
Chen, S	1
Pal, I	1
Dey, KK	1
Chaurasia, M	1
Parida, S	1
Das, S	2
Rajesh, Y	1
Sharma, K	1
Chowdhury, T	1
Mandal, M	4
Bazan, L	1
Bendas, ER	1
El Gazayerly, ON	1
Badawy, SS	1
Li, W	1
Liu, D	2
Zhang, H	1
Correia, A	1
Mäkilä, E	1
Salonen, J	1
Hirvonen, J	1
Santos, HA	1
Schiffmann, S	1
Maier, TJ	3
Wobst, I	1
Janssen, A	2
Corban-Wilhelm, H	1
Angioni, C	1
Geisslinger, G	4
Grösch, S	4
Gradilone, A	1
Pulcinelli, FM	1
Lotti, LV	1
Trifirò, E	1
Martino, S	1
Gandini, O	1
Gianni, W	1
Frati, L	1
Aglianò, AM	1
Gazzaniga, P	1
Fatima, N	2
Yi, M	1
Ajaz, S	1
Stephens, RM	1
Stauffer, S	2
Greenwald, P	2
Munroe, DJ	1
Ali, IU	2
Takahashi-Yanaga, F	2
Yoshihara, T	1
Jingushi, K	1
Miwa, Y	2
Morimoto, S	2
Sasaguri, T	2
Banning, A	1
Kipp, A	1
Schmitmeier, S	1
Löwinger, M	1
Florian, S	1
Krehl, S	1
Thalmann, S	1
Thierbach, R	1
Steinberg, P	1
Brigelius-Flohé, R	1
Zhao, S	1
Cai, J	1
Bian, H	1
Gui, L	1
Zhao, F	1
Foreman, JE	1
Sorg, JM	1
McGinnis, KS	1
Rigas, B	1
Williams, JL	1
Clapper, ML	2
Gonzalez, FJ	1
Peters, JM	1
Yan, M	1
Myung, SJ	1
Lawrence, E	1
Lutterbaugh, J	1
Zhou, X	1
Rerko, RM	1
Willis, J	1
Dawson, D	1
Tai, HH	1
Newman, RA	1
Bertagnolli, MM	2
Yang, Z	1
Xiao, H	2
Jin, H	1
Koo, PT	1
Tsang, DJ	1
Yang, CS	2
Bozzo, F	3
Bassignana, A	2
Lazzarato, L	1
Boschi, D	1
Gasco, A	1
Bocca, C	3
Miglietta, A	3
Winfield, LL	1
Inniss, TR	1
Smith, DM	1
Guruswamy, S	1
Rao, CV	10
Venkatesan, P	3
Krishnan, MM	1
Chakraborty, C	1
Chaudhury, K	2
Kanwar, SS	1
Roy, KR	1
Reddanna, P	1
Lynch, PM	1
Ayers, GD	1
Hawk, E	1
Richmond, E	1
Eagle, C	1
Woloj, M	1
Church, J	1
Hasson, H	1
Patterson, S	1
Half, E	1
Burke, CA	1
Carothers, AM	1
Davids, JS	1
Damas, BC	1
Liu, JP	2
Wei, HB	2
Zheng, ZH	2
Guo, WP	2
Fang, JF	2
Gao, P	1
Guan, L	1
Zheng, J	1
Puvvada, N	1
Dash, R	2
Prashanth Kumar, BN	1
Sarkar, D	2
Azab, B	1
Pathak, A	1
Kundu, SC	1
Fisher, PB	2
Sade, A	1
Tunçay, S	1
Cimen, I	1
Severcan, F	1
Banerjee, S	1
Gravitz, L	1
Kim, YM	2
Pyo, H	2
Cannito, S	1
Parola, M	1
Choudry, HA	1
Mavanur, A	1
O'Malley, ME	1
Zeh, HJ	1
Guo, Z	1
Bartlett, DL	1
Lubet, RA	2
McCormick, DL	1
Pereira, MA	2
Chang, WC	1
Steele, VE	3
Fischer, SM	1
Juliana, MM	1
Grubbs, CJ	1
van Heumen, BW	1
Roelofs, HM	1
Te Morsche, RH	1
Marian, B	1
Nagengast, FM	1
Peters, WH	1
Kang, SN	1
Hong, SS	1
Lee, MK	1
Lim, SJ	1
Rahman, M	1
Selvarajan, K	1
Hasan, MR	1
Chan, AP	1
Jin, C	1
Kim, J	1
Chan, SK	1
Le, ND	1
Kim, YB	1
Tai, IT	1
Bhutia, SK	1
Singh, AK	1
Das, SK	1
Deng, Y	1
Su, Q	1
Mo, J	1
Fu, X	1
Lin, EH	1
Zhang, DQ	1
Guo, Q	1
Zhu, JH	1
Chen, WC	1
Femia, AP	1
Dolara, P	1
Salvadori, M	1
Caderni, G	1
Swamy, MV	3
Herzog, CR	1
Yasumaru, M	2
Tsuji, S	2
Tsujii, M	2
Irie, T	2
Komori, M	1
Kimura, A	1
Nishida, T	2
Kakiuchi, Y	2
Kawai, N	1
Murata, H	2
Horimoto, M	1
Sasaki, Y	1
Hayashi, N	2
Kawano, S	2
Hori, M	1
Davis, TW	1
O'Neal, JM	1
Pagel, MD	1
Zweifel, BS	2
Mehta, PP	1
Heuvelman, DM	1
Masferrer, JL	2
Cooma, I	2
Patlolla, JM	2
Simi, B	3
Reddy, BS	9
Schilling, K	1
Schmidt, R	2
Schönthal, AH	1
Tao, L	1
Wang, W	1
Li, Y	1
Umar, A	1
Thompson, CA	1
Roy, HK	1
Kim, YL	1
Wali, RK	1
Liu, Y	1
Koetsier, J	1
Kunte, DP	1
Goldberg, MJ	1
Backman, V	1
Do, K	1
Barnard, GF	1
Wang, SH	1
Ogunwobi, OO	1
Beales, IL	2
Casanova, I	1
Parreño, M	1
Farré, L	1
Guerrero, S	1
Céspedes, MV	1
Pavon, MA	1
Sancho, FJ	1
Marcuello, E	1
Trias, M	1
Mangues, R	1
Ogunwobi, O	1
Wang, CX	1
Kong, AN	1
Khor, TO	1
Zheng, X	1
Wang, CH	1
Ouyang, Q	1
Tang, CW	1
Huang, MH	1
Li, X	1
Lou, J	1
Xiao, Z	1
Smythers, G	1
Zell, JA	1
Ignatenko, NA	1
Yerushalmi, HF	1
Ziogas, A	1
Besselsen, DG	1
Gerner, EW	1
Anton-Culver, H	1
Cianchi, F	1
Cortesini, C	1
Magnelli, L	1
Fanti, E	1
Papucci, L	1
Schiavone, N	1
Messerini, L	1
Vannacci, A	1
Capaccioli, S	1
Perna, F	1
Lulli, M	1
Fabbroni, V	1
Perigli, G	1
Bechi, P	1
Masini, E	1
Sakoguchi-Okada, N	1
Fukada, K	1
Shiraishi, F	1
Taba, Y	1
Iida, M	1
Lev-Ari, S	1
Kazanov, D	1
Liberman, E	1
Ben-Yosef, R	1
Arber, N	1
Amos-Landgraf, JM	1
Kwong, LN	1
Kendziorski, CM	1
Reichelderfer, M	1
Torrealba, J	1
Weichert, J	1
Haag, JD	1
Chen, KS	1
Waller, JL	1
Gould, MN	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975]	Phase 2	35 participants (Anticipated)	Interventional	2022-05-02	Recruiting
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer[NCT01150045]	Phase 3	2,527 participants (Actual)	Interventional	2010-06-30	Active, not recruiting
Phase I Pilot Toxicity/Methods Validation Study of Celecoxib in Genotype-Positive Children With Familial Adenomatous Polyposis[NCT00685568]	Phase 1	22 participants (Actual)	Interventional	2002-11-21	Completed
Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2002-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Disease-Free Survival (DFS) is defined as the time of randomization until documented progression or death from any cause. The endpoint of this trial is to compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive and disease free after 3 years are reported here. A log-rank test stratified with the stratification factors was used to compare disease-free survival (celecoxib vs placebo) (NCT01150045)
Timeframe: At 3 years of follow-up

Overall Survival

Intervention	percentage of participants (Number)
FOLFOX and Placebo (Arms A +C)	73.4
FOLFOX Plus Celecoxib Daily (Arms B + D)	76.3

Overall Survival (DFS) is defined as the time of randomization until documented death from any cause. The endpoint is to compare overall survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 5 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive after 3 years are reported here. (NCT01150045)
Timeframe: up to 3 years from registration

Response as Evaluated by Recurrence of Diseases

Intervention	percentage of participants (Number)
FOLFOX and Placebo (Arms A +C)	81.6
FOLFOX Plus Celecoxib Daily (Arms B + D)	84.3

Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)

Toxicity of Celecoxib With Concurrent Weekly Chemotherapy and Radiotherapy in the Treatment of Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Intervention	Participants (Number)
	Local Control Only	Local Control and Distant Metastasis	Distant Metastatsis Only	Secondary Primary - Site Unknown	Surgical Salvage
Recurrence	6	2	1	2	3

Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy

Article	Year
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA, 2021, 04-06, Volume: 325, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemother	2021
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA, 2021, 04-06, Volume: 325, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemother	2021
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA, 2021, 04-06, Volume: 325, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemother	2021
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA, 2021, 04-06, Volume: 325, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemother	2021
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proceedings of the National Academy of Sciences of the United States of America, 2009, Jun-09, Volume: 106, Issue:23 Topics: Adenoma; Animals; Celecoxib; Colon; Colonic Neoplasms; Colonoscopy; Drug and Narcotic Control; Human	2009
The safety and efficacy of celecoxib in children with familial adenomatous polyposis. The American journal of gastroenterology, 2010, Volume: 105, Issue:6 Topics: Adenoma; Adenomatous Polyposis Coli; Adolescent; Celecoxib; Child; Cohort Studies; Colonic Neoplasms	2010

Article	Year
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I. Bioorganic & medicinal chemistry letters, 2005, Sep-01, Volume: 15, Issue:17 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 1; Cy	2005
A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors. Bioorganic & medicinal chemistry letters, 2011, Nov-15, Volume: 21, Issue:22 Topics: Animals; Benzenesulfonamides; Caco-2 Cells; Celecoxib; Clostridium perfringens; Colon; Colonic Neopl	2011
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker. Bioorganic & medicinal chemistry letters, 2013, Jan-01, Volume: 23, Issue:1 Topics: Acridines; Acridones; Biomarkers, Tumor; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygen	2013
Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorganic & medicinal chemistry, 2013, May-01, Volume: 21, Issue:9 Topics: Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Cell Proliferation; Colonic Ne	2013
Effects of the anti-inflammatory drug celecoxib on cell death signaling in human colon cancer. Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:6 Topics: Anti-Inflammatory Agents; Apoptosis; Celecoxib; Cell Death; Colonic Neoplasms; Cyclooxygenase 2 Inhi	2023
ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells. Cancer medicine, 2023, Volume: 12, Issue:16 Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Humans; Thiones	2023
Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. International journal of molecular sciences, 2019, Nov-28, Volume: 20, Issue:23 Topics: Adult; Aged; alpha-Tocopherol; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Colonic Neoplasms	2019
Celecoxib Targeted Therapy Attenuates Mouse Colon Carcinogenesis through Modulation of Expression Patterns of Cancer Stem Cells. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2019, Volume: 38, Issue:4 Topics: 1,2-Dimethylhydrazine; Animals; Carcinogenesis; Carcinogens; Celecoxib; Colonic Neoplasms; Cyclooxyg	2019
Insight into the Colonic Disposition of Sulindac in Humans. Journal of pharmaceutical sciences, 2021, Volume: 110, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Neoplasms; Colorectal Neoplasms; Humans;	2021
Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis. Matrix biology : journal of the International Society for Matrix Biology, 2021, Volume: 95 Topics: Animals; Azoxymethane; beta Catenin; Cadherins; Cancer-Associated Fibroblasts; Celecoxib; Colitis-As	2021
Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/β-catenin signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 84 Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; beta Catenin; Celecoxib; Cell L	2021
Celecoxib alleviates zinc deficiency-promoted colon tumorigenesis through suppressing inflammation. Aging, 2021, 03-03, Volume: 13, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Celecoxib; Colonic Neoplasms; Infl	2021
Celecoxib for Stage III Colon Cancer. JAMA, 2021, 04-06, Volume: 325, Issue:13 Topics: Celecoxib; Colonic Neoplasms; Disease-Free Survival; Humans; Reference Standards; Sulfonamides	2021
Role of GSK-3β in Regulation of Canonical Wnt/β-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer. Cancer investigation, 2017, Aug-09, Volume: 35, Issue:7 Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Transformation,	2017
Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. ChemMedChem, 2019, 02-05, Volume: 14, Issue:3 Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Su	2019
Dolastatin, along with Celecoxib, stimulates apoptosis by a mechanism involving oxidative stress, membrane potential change and PI3-K/AKT pathway down regulation. Biochimica et biophysica acta, 2013, Volume: 1830, Issue:11 Topics: Adenosine Triphosphate; Animals; Apoptosis; Binding Sites; Celecoxib; Cell Cycle Proteins; Colonic N	2013
Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:1 Topics: 1,2-Dimethylhydrazine; Animals; Celecoxib; Colitis, Ulcerative; Colonic Neoplasms; Cyclooxygenase 2	2014
Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies. ChemMedChem, 2014, Volume: 9, Issue:1 Topics: 4-Chloro-7-nitrobenzofurazan; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor;	2014
Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression. PloS one, 2014, Volume: 9, Issue:6 Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells;	2014
Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-re The Journal of biological chemistry, 2014, Aug-01, Volume: 289, Issue:31 Topics: Activating Transcription Factor 3; Apoptosis; Base Sequence; Celecoxib; Cell Line, Tumor; Colonic Ne	2014
The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:6 Topics: Animals; Celecoxib; Chemoprevention; Colitis; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Mice;	2014
COX-2- and endoplasmic reticulum stress-independent induction of ULBP-1 and enhancement of sensitivity to NK cell-mediated cytotoxicity by celecoxib in colon cancer cells. Experimental cell research, 2015, Jan-15, Volume: 330, Issue:2 Topics: AC133 Antigen; Antigens, CD; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi	2015
Celecoxib prevents colitis associated colon carcinogenesis: an upregulation of apoptosis. Pharmacological reports : PR, 2014, Volume: 66, Issue:6 Topics: Apoptosis; Celecoxib; Cell Cycle Checkpoints; Cell Proliferation; Colitis, Ulcerative; Colon; Coloni	2014
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs. Carcinogenesis, 2015, Volume: 36, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carc	2015
Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation. Oncotarget, 2015, May-20, Volume: 6, Issue:14 Topics: Blotting, Western; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclooxygenas	2015
The interplay between GRP78 expression and Akt activation in human colon cancer cells under celecoxib treatment. Anti-cancer drugs, 2015, Volume: 26, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Chromones; Colonic Neoplasms; Endopla	2015
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. Drug design, development and therapy, 2015, Volume: 9 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Azepines; Camptothecin; Celec	2015
Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5 Topics: Apoptosis; Benzimidazoles; Carcinoma; Celecoxib; Colonic Neoplasms; Combined Modality Therapy; DNA B	2016
Expression Patterns of Cancer Stem Cell Markers During Specific Celecoxib Therapy in Multistep Rat Colon Carcinogenesis Bioassays. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:3 Topics: Aldehyde Dehydrogenase 1 Family; Animals; Biological Assay; Biomarkers, Tumor; Carcinogenesis; Celec	2016
Comparative pharmaceutical study on colon targeted micro-particles of celecoxib: in-vitro-in-vivo evaluation. Drug delivery, 2016, Volume: 23, Issue:9 Topics: Acetic Acid; Acrylic Resins; Animals; Celecoxib; Chemistry, Pharmaceutical; Colon; Colonic Neoplasms	2016
Microfluidic assembly of a nano-in-micro dual drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy. Acta biomaterialia, 2017, 01-15, Volume: 48 Topics: Aluminum Silicates; Atorvastatin; Caco-2 Cells; Celecoxib; Cell Death; Cell Proliferation; Cell Surv	2017
Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2016, Volume: 35, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Celecoxib; Col	2016
The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochemical pharmacology, 2008, Jul-15, Volume: 76, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; beta Catenin; Celecoxib; Cell Cycle; Ce	2008
Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Current cancer drug targets, 2008, Volume: 8, Issue:5 Topics: ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Celecoxib; Cell Membrane; Cell Sur	2008
Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2008, Volume: 17, Issue:11 Topics: Blotting, Western; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Gene	2008
Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells. Biochemical and biophysical research communications, 2008, Dec-26, Volume: 377, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Celecoxib; Cell Line, Tumor; Colonic Neoplasm	2008
Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice. Cancer research, 2008, Dec-01, Volume: 68, Issue:23 Topics: Adenocarcinoma; Animals; Celecoxib; Cell Growth Processes; Cell Movement; Colonic Neoplasms; Cycloox	2008
Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. Cancer investigation, 2009, Volume: 27, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Celecoxib; Cell Pr	2009
Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Molecular carcinogenesis, 2009, Volume: 48, Issue:10 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Blotting, Western; Celecoxib; Coloni	2009
Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. International journal of cancer, 2010, Feb-15, Volume: 126, Issue:4 Topics: Atorvastatin; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Chromans; Colonic Neoplasms; C	2010
Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth. Chemico-biological interactions, 2009, Dec-10, Volume: 182, Issue:2-3 Topics: beta Catenin; Cadherins; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neo	2009
Structure activity relationship of antiproliferative agents using multiple linear regression. Chemical biology & drug design, 2009, Volume: 74, Issue:3 Topics: Algorithms; Antineoplastic Agents; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2	2009
Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. International journal of oncology, 2009, Volume: 35, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caveolin 1; Celecoxib;	2009
Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques. Micron (Oxford, England : 1993), 2010, Volume: 41, Issue:3 Topics: Antineoplastic Agents; Celecoxib; Cell Shape; Colonic Neoplasms; Cytoskeleton; Epithelial Cells; Hum	2010
Na(+)-stimulated Na+/H+ exchange and an unfavorable Ca2+ homeostasis initiate the cycloxygenase-2 inhibitors-induced apoptotic signals in colonic epithelial cells during the early stage of colon carcinogenesis. Oncology research, 2009, Volume: 18, Issue:5-6 Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; Calcium; Caspases; Celecoxib; Colon; Colonic Neoplasms; C	2009
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer research, 2010, Jun-01, Volume: 70, Issue:11 Topics: Animals; Antigens, CD34; Celecoxib; Cell Transformation, Neoplastic; Colitis; Colonic Neoplasms; Cyc	2010
Celecoxib increases retinoid sensitivity in human colon cancer cell lines. Cellular & molecular biology letters, 2010, Volume: 15, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Line, Tumor; Colonic Neop	2010
Antiproliferative effect of a novel nitro-oxy derivative of celecoxib in human colon cancer cells: role of COX-2 and nitric oxide. Anticancer research, 2010, Volume: 30, Issue:7 Topics: Apoptosis; Benzyl Compounds; beta Catenin; Celecoxib; Cell Growth Processes; Cell Membrane; Cell Nuc	2010
Role of leukotriene B4 in celecoxib-mediated anticancer effect. Biochemical and biophysical research communications, 2010, Nov-12, Volume: 402, Issue:2 Topics: Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neopl	2010
[Celecoxib increased cellular ATRA sensitivity of human colon cancer cell lines through COX-2-independent mechanisms]. Yao xue xue bao = Acta pharmaceutica Sinica, 2009, Volume: 44, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cyc	2009
The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials, 2011, Volume: 32, Issue:15 Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Cycle; Cell Proliferation; Chitosan; Colonic Neoplas	2011
Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression. Bioscience reports, 2012, Volume: 32, Issue:1 Topics: Antineoplastic Agents; Celecoxib; Cell Membrane; Cell Movement; Cell Proliferation; Colonic Neoplasm	2012
Chemoprevention: First line of defence. Nature, 2011, Mar-24, Volume: 471, Issue:7339 Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I	2011
Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines. DNA and cell biology, 2012, Volume: 31, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Ben	2012
Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Molecular carcinogenesis, 2012, Volume: 51, Issue:10 Topics: beta Catenin; Cadherins; Celecoxib; Cell Hypoxia; Cell Proliferation; Colonic Neoplasms; Cyclooxygen	2012
Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei. Annals of surgical oncology, 2012, Volume: 19, Issue:5 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Appendiceal Neoplasms; Celecoxib; Colonic N	2012
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Oncology reports, 2012, Volume: 27, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Co	2012
Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. Experimental cell research, 2012, Apr-15, Volume: 318, Issue:7 Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cele	2012
Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, West	2012
Dual function of tributyrin emulsion: solubilization and enhancement of anticancer effect of celecoxib. International journal of pharmaceutics, 2012, May-30, Volume: 428, Issue:1-2 Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms;	2012
Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-κB and an inflammatory protein, iNOS. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2012, Volume: 21, Issue:6 Topics: Animals; Apoptosis; Blotting, Western; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenas	2012
Up-regulation of p53 and mitochondrial signaling pathway in apoptosis by a combination of COX-2 inhibitor, Celecoxib and Dolastatin 15, a marine mollusk linear peptide in experimental colon carcinogenesis. Molecular carcinogenesis, 2013, Volume: 52, Issue:11 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcino	2013
Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:7 Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Aspirin; ATP Binding Cassette Transporter, S	2012
AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells. Life sciences, 2012, Oct-22, Volume: 91, Issue:15-16 Topics: Actins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C	2012
Celecoxib downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells. Cancer investigation, 2013, Volume: 31, Issue:2 Topics: AC133 Antigen; Antigens, CD; Celecoxib; Cell Differentiation; Cell Line, Tumor; Cell Proliferation;	2013
Different cell cycle modulation by celecoxib at different concentrations. Cancer biotherapy & radiopharmaceuticals, 2013, Volume: 28, Issue:2 Topics: Adenocarcinoma; Apoptosis; Celecoxib; Cell Cycle; Cell Proliferation; Colonic Neoplasms; Cyclooxygen	2013
Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World journal of surgical oncology, 2013, Jan-24, Volume: 11 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;	2013
Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin. BMC cancer, 2013, Feb-01, Volume: 13 Topics: 1,2-Dimethylhydrazine; Adenoma; Animals; beta Catenin; Biomarkers, Tumor; Celecoxib; Cell Nucleus; C	2013
New combination promising against colon cancer. Expert review of anticancer therapy, 2001, Volume: 1, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe	2001
Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer research, 2003, Sep-01, Volume: 63, Issue:17 Topics: Antineoplastic Agents; Celecoxib; Cell Division; Cell Nucleus; Colonic Neoplasms; Cyclin-Dependent K	2003
Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer research, 2003, Oct-15, Volume: 63, Issue:20 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals;	2003
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer research, 2004, Jan-01, Volume: 64, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinoma; Celecoxib; Colonic Neoplasms; Combined Modality Therapy;	2004
Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Molecular cancer therapeutics, 2004, Volume: 3, Issue:2 Topics: Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxy	2004
Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochemical pharmacology, 2004, Apr-15, Volume: 67, Issue:8 Topics: Anticarcinogenic Agents; Apoptosis; Caco-2 Cells; Celecoxib; Cell Cycle; Cell Cycle Proteins; Cell S	2004
Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003;63:5239-42. Cancer research, 2004, Apr-15, Volume: 64, Issue:8 Topics: Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; Cyclooxygenase	2004
Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis, 2004, Volume: 25, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azoxymethane; Biomarkers, Tumor; Carcinogen	2004
COX-2 inhibitors still eyed for cancer prevention. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, May-01, Volume: 62, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Celecoxib; Colonic Neoplasms; Cycl	2005
Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:10 Topics: Adenomatous Polyposis Coli Protein; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents	2005
Spectral markers in preneoplastic intestinal mucosa: an accurate predictor of tumor risk in the MIN mouse. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2005, Volume: 14, Issue:7 Topics: Animals; Celecoxib; Colonic Neoplasms; Cyclooxygenase Inhibitors; Intestinal Mucosa; Male; Mice; Mic	2005
Effect of concomitant polyethylene glycol and celecoxib on colonic aberrant crypt foci and tumors in F344 rats. Digestive diseases and sciences, 2005, Volume: 50, Issue:7 Topics: Animals; Azoxymethane; Bromodeoxyuridine; Celecoxib; Colon; Colonic Neoplasms; Cyclooxygenase Inhibi	2005
Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer research, 2005, Sep-01, Volume: 65, Issue:17 Topics: Animals; Azoxymethane; Carcinogens; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2	2005
Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways. Regulatory peptides, 2006, Mar-15, Volume: 134, Issue:1 Topics: Apoptosis; Celecoxib; Cell Count; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxyg	2006
Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. International journal of cancer, 2006, May-15, Volume: 118, Issue:10 Topics: Anoikis; Carcinoma; Celecoxib; Cell Nucleus; Colonic Neoplasms; Crk-Associated Substrate Protein; Cy	2006
Glycine-extended gastrin inhibits apoptosis in colon cancer cells via separate activation of Akt and JNK pathways. Molecular and cellular endocrinology, 2006, Mar-09, Volume: 247, Issue:1-2 Topics: Anthracenes; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Survival; Chromones; Colonic Neoplasms; Ga	2006
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer research, 2006, Apr-15, Volume: 66, Issue:8 Topics: Animals; Anticarcinogenic Agents; Apoptosis; Aspirin; Atorvastatin; Azoxymethane; Carcinogens; Celec	2006
[Effects of selective and non-selective cyclooxygenase-2 inhibitor on the growth of colon cancer cells]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2006, Volume: 37, Issue:4 Topics: Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclooxygena	2006
Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006, Volume: 15, Issue:9 Topics: Blotting, Western; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycl	2006
Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. International journal of cancer, 2007, Feb-01, Volume: 120, Issue:3 Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal	2007
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Molecular cancer therapeutics, 2006, Volume: 5, Issue:11 Topics: Aged; Animals; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; bcl-2-Associated X Protein; Caco-	2006
Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochemical pharmacology, 2007, May-01, Volume: 73, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Celecoxib; Colonic Neoplasms; Cyclin D1; Gene	2007
Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines. Digestive diseases and sciences, 2007, Volume: 52, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Carcinoma; Celecoxib; Cel	2007
A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, Mar-06, Volume: 104, Issue:10 Topics: Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Col	2007
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. International journal of cancer, 2007, Aug-15, Volume: 121, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colonic Neoplasms; Cyclooxygenas	2007
Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World journal of gastroenterology, 2007, Apr-07, Volume: 13, Issue:13 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apo	2007
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochemical pharmacology, 2008, Jan-15, Volume: 75, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; Cisplatin; Colonic Neo	2008
Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression. British journal of pharmacology, 2008, Volume: 153, Issue:6 Topics: Blotting, Western; Celecoxib; Cell Adhesion; Cells, Cultured; Colonic Neoplasms; Cyclooxygenase Inhi	2008
Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). British journal of pharmacology, 2008, Volume: 153, Issue:5 Topics: Apoptosis; Celecoxib; Cell Adhesion; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors;	2008
Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Molecular carcinogenesis, 2008, Volume: 47, Issue:7 Topics: Apoptosis; Celecoxib; Cell Adhesion Molecules; Cell Proliferation; Colonic Neoplasms; Cyclic GMP; Cy	2008
Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. International journal of cancer, 2008, May-01, Volume: 122, Issue:9 Topics: Apoptosis; Atorvastatin; Celecoxib; Cell Cycle; Cell Survival; Colonic Neoplasms; Cyclooxygenase Inh	2008
Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer research, 2008, Feb-15, Volume: 68, Issue:4 Topics: Aspirin; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Glycogen Synth	2008
Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Experimental oncology, 2008, Volume: 30, Issue:1 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Proliferation; Colonic Ne	2008
Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention. Journal of the National Cancer Institute, 2008, Jun-04, Volume: 100, Issue:11 Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Prot	2008
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer research, 1998, Feb-01, Volume: 58, Issue:3 Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cycl	1998
[APHS and celecoxib, the new aspirins have arrived]. Bulletin du cancer, 1998, Volume: 85, Issue:7 Topics: Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibito	1998
Early trials probe COX-2 inhibitors' cancer-fighting potential. Journal of the National Cancer Institute, 1999, Jul-21, Volume: 91, Issue:14 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Colonic Neoplasms; Cyc	1999
Colon cancer prevention. Worth the trouble. Harvard health letter, 1999, Volume: 25, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colonic Neoplasms; Diet; Female;	1999
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer research, 2000, Jan-15, Volume: 60, Issue:2 Topics: Administration, Oral; Animals; Anticarcinogenic Agents; Azoxymethane; Celecoxib; Colonic Neoplasms;	2000
Proapoptotic anti-inflammatory drugs. Urology, 2001, Volume: 57, Issue:4 Suppl 1 Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Ce	2001
Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. Japanese journal of cancer research : Gann, 2001, Volume: 92, Issue:6 Topics: Animals; Anticarcinogenic Agents; Azoxymethane; beta Catenin; Celecoxib; Cell Division; Cell Nucleus	2001
COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:14 Topics: Animals; Apoptosis; Blotting, Western; Caco-2 Cells; Celecoxib; Cell Cycle; Cell Cycle Proteins; Cel	2001
Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer research, 2002, Jan-01, Volume: 62, Issue:1 Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Body Weight; Carcinogens; Celecoxib; Colon; Colonic	2002
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer research, 2002, Feb-01, Volume: 62, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Coloni	2002
Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. International journal of oncology, 2002, Volume: 20, Issue:4 Topics: Apoptosis; Caspase 3; Caspases; Celecoxib; Cell Survival; Colonic Neoplasms; Cyclooxygenase Inhibito	2002
Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. The Journal of biological chemistry, 2002, Aug-02, Volume: 277, Issue:31 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Apoptosis; Celecoxib; Cell Survival; Colonic Neoplasms	2002
COX-2 and prostanoid receptors: good targets for chemoprevention. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2002, Volume: 21, Issue:2 Topics: Animals; Breast Neoplasms; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Colonic Neop	2002

celecoxib and Cancer of Colon